European Archives - Page 138 of 1534 - European Medical Journal

machine learning

Machine Learning Maps COVID Vaccine Responses in HIV

Machine learning reveals unique COVID vaccine immune signatures in people living with HIV, with differences in antibodies, cytokines, and T cell responses.

COVID-19

Post-COVID Liver Complications Revealed

Post-COVID chronic liver complications, including fibrosis and cirrhosis, have been reported months after infection, highlighting long-term risks.

Could AI Aid Identification of Vertebral Fractures?

AI tools may help detect vertebral fractures on CT scans, matching expert accuracy and improving osteoporosis care.

Invasive Fungal Infections: Past, Present, Future

This symposium celebrates 35 years of amphotericin B (AmBisome) in clinical practice, examining its enduring role in treating invasive…

Natural History of a Giant Bladder Stone

The authors report the case of an 80-year-old Canadian male with a giant bladder stone who declined treatment. A bladder stone is…

Copenhagen Denmark

Lundbeck taps Markus Kede as first Chief AI Officer

The appointment is tied to the company’s “focused innovator” strategy, seeking to combine human expertise with high-performance computing.

Cardiomyocyte TGFB3 Preserves Cardiac Function in Heart Failure

Cardiomyocyte TGFB3 Preserves Cardiac Function in Heart Failure

In the absence of cardiomyocyte TGFB3, the study observed increased expression of profibrotic mediators including connective tissue growth factor (CTGF) and SERPINE1.

Depression and Visual Impairment Raise Cardiovascular Disease Risk

Participants with depression alone had the highest risk (HR: 1.60; 95% CI: 1.36–1.89), followed by those with both depression and VI (HR 1.56; 95% CI: 1.40–1.73).

Space satellite in space

UK opens door to pharma manufacturing in space

The UK Space Agency, MHRA and the CAA have announced a new regulatory roadmap for in-orbit manufacturing of pharmaceuticals.

weight loss drugs

Two-Thirds of Weight Loss Drug Users Treat in Secret

Two-thirds of patients on GLP-1 drugs hide their treatment from loved ones, with varying stigma across social and gender differences.